Pharmacological manipulation of RXFP3 alters feeding behaviors in rodents, identifying RXFP3 as a promising therapeutic target for treating obesity and other eating disorders (McGowan et al., 2005, 2006; Ganella et al., 2012, 2013; Smith et al., 2014; De Ávila et al., 2018). This evidence concerns the gene RXFP3 and obesity due to melanocortin 4 receptor deficiency.